WHO ICTRP trial
A study on the efficacy and safety of transcather arterial infusion chemotherapy…
ChiCTR2000033353 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000033353 |
|---|---|
| Public title | A study on the efficacy and safety of transcather arterial infusion chemotherapy combined with camrelizumab followed embolization in the treatment of HCC |
| Scientific title | A study on the efficacy and safety of transcather arterial infusion chemotherapy combined with camrelizumab followed embolization in the treatment of primary hepatocellular carcinoma |
| Primary sponsor | Shijiazhuang Ping'an Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Hepatocellular Carcinoma |
| Interventions | Experimental Group:camrelizumab |
| Registration date | May 29, 2020 |
| Target size | Experimental Group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: